Tubulis generates uniquely matched Antibody Drug Conjugates (ADCs) based on proprietary and broadly patent protected next-generation conjugation and linker-payload platforms.
Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight.
Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication.
Tubulis will build new conjugates to fill its pipeline and will collaborate with partners to usher in a new ADC era and deliver better outcomes for patients.
Address
Tubulis GmbH
Butenandtstr. 1
81375 Munich
Germany
Phone: +49 1723 505125
Internet: www.tubulis.com
Pipeline
We are currently advancing three ADC assets:
TUB-010 | Lymphoma, pre-IND; ready for partnering
TUB-030 | solid cancer, discovery
TUB-040 | solid cancer, discovery
Strong technology portfolio
Tub-tag and P5 by Tubulis - one company, two unique, complementing ADC conjugation technologies fulfilling the needs of 3rd generation ADCs:
Click here if you notice an image that violates copyright or privacy rights.
We only use functionally necessary cookies and the web analysis tool Matomo in order to optimally design and continuously improve our website for you. By continuing to use our website, you agree to this. Further information and an objection possibility can be found here: Data protection